Phytocannabinoïds: Therapeutic potential, mechanism of action, and regulatory challenges
1 Pharmacognosy Laboratory, Faculty of Pharmacy, University of Health Sciences, Algiers, Algeria.
2 Pharmacy Department, Hussein Dey University Hospital, Algiers, Algeria.
Research Article
GSC Advanced Research and Reviews, 2024, 21(01), 180–184.
Article DOI: 10.30574/gscarr.2024.21.1.0364
Publication history:
Received on 29 August 2024; revised on 13 October 2024; accepted on 15 October 2024
Abstract:
Phytocannabinoïds, notably cannabidiol (CBD) and tetrahydrocannabinol (THC), are the primary active compounds in the Cannabis sativa plant. These compounds interact with the endocannabinoid system in humans, which regulates various physiological processes. The scientific exploration of phytocannabinoïds has expanded significantly due to their potential therapeutic effects. Concurrently, regulatory frameworks are evolving to accommodate the increasing medicinal use of these compounds.
A comprehensive review of peer-reviewed literature was conducted to evaluate the therapeutic effects, mechanisms of action, and safety profiles of phytocannabinoïds. Regulatory documents and policy papers from multiple countries were analyzed to understand the legal status and regulatory approaches toward phytocannabinoïds. Data sources included PubMed, regulatory agency websites, and international health organization reports.
The review highlighted that CBD and THC exhibit significant promise in treating conditions such as epilepsy, chronic pain, multiple sclerosis, and anxiety. CBD is generally well-tolerated with a favorable safety profile, while THC, despite its psychoactive effects, has demonstrated efficacy in pain management and muscle spasticity. Regulatory landscapes vary widely, with countries like Canada and Uruguay fully legalizing cannabis, while others, such as the United States, maintain a complex legal framework with federal restrictions but state-level legalization. This fragmentation poses challenges for researchers and healthcare providers.
Phytocannabinoïds present a substantial opportunity for therapeutic advancement, supported by growing scientific evidence. However, the regulatory environment remains inconsistent, necessitating harmonization to facilitate research and clinical application. Future efforts should focus on robust clinical trials to establish definitive efficacy and safety profiles and on developing coherent regulatory policies that balance public health concerns with the therapeutic potential of phytocannabinoïds.
Keywords:
Phytocannabinoïds; Regulatory framework; Endocannabinoid receptors; Therapeutic effects; Cannabis sativa
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0